Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
22 Agosto 2023 - 5:05PM
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the
“Company”) today announced that Scott Tarriff, Chief Executive
Officer, and Brian Cahill, Chief Financial Officer, will present at
the following healthcare conferences:
Citi's 2023 18th
Annual BioPharma Conference
Date: |
Thursday,
September 7, 2023 |
Time: |
8:00AM ET |
Webcast: |
Click here |
H.C. Wainwright 25th
Annual Global Investment Conference
Date: |
Tuesday,
September 12, 2023 |
Time: |
2:00PM ET |
Webcast: |
Click here |
To schedule a 1x1 meeting with management, please contact your
Corporate Access representative.
The webcasts of the presentations will be accessible for 30 days
thereafter, via the Company’s website at www.eagleus.com, under the
Investors section.
About Eagle Pharmaceuticals, Inc. Eagle is a
fully integrated pharmaceutical company with research and
development, clinical, manufacturing and commercial expertise.
Eagle is committed to developing innovative medicines that result
in meaningful improvements in patients’ lives. Eagle’s
commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®,
BELRAPZO®, TREAKISYM® (Japan), and Byfavo® and Barhemsys® through
its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and
CNS/metabolic critical care pipeline includes product candidates
with the potential to address underserved therapeutic areas across
multiple disease states. Additional information is available on
Eagle’s website at www.eagleus.com.
Investor Relations for Eagle Pharmaceuticals,
Inc.: Lisa M. WilsonIn-Site Communications, Inc. T:
212-452-2793 E: lwilson@insitecony.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024